[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100333482":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":24,"centralContacts":36,"locations":43,"responsibleParty":63,"collaborators":65,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":107,"studyType":108,"phases":10,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Radboud University Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EC patients with HT",null,"Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy",[13],"Drug: Hormonal Antineoplastics",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Hormonal Antineoplastics","Hormonal therapy used for treatment in endometrial cancer patients",[9],[21,22,23],"Progesterone","Tamoxifen","Aromatase inhibitors",[25,28,31,34],{"name":26,"affiliation":5,"role":27},"Hanny Pijnenborg, MD PhD","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":30,"role":27},"Roy Lalisang, MD PhD prof","Maastricht University Medical Center",{"name":32,"affiliation":33,"role":27},"Andrea Romano, MD PhD","Maastricht University",{"name":35,"affiliation":5,"role":27},"Willem Jan Van Weelden, MD",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Maartje Luijten, MD","CONTACT","+31243616683","Maartje.luijten@radboudumc.nl",{"name":26,"role":39,"phone":40,"phoneExt":10,"email":10},[44],{"facility":45,"status":46,"city":47,"state":10,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Radboudumc","RECRUITING","Nijmegen","6525GA","Netherlands","NL",{"type":52,"coordinates":53},"Point",[54,55],5.85278,51.8425,{"lat":55,"lon":54},[58,60],{"name":59,"role":39,"phone":10,"phoneExt":10,"email":41},"Maartje Luijten",{"name":61,"role":39,"phone":10,"phoneExt":10,"email":62},"Hanny Pijnenborg","Hanny.ma.pijnenborg@radboudumc.nl",{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[66,68,69,71,74,76,78,80,82,84,86,88,90,92],{"name":67,"class":6},"Haukeland University Hospital",{"name":30,"class":6},{"name":70,"class":6},"Brno University Hospital",{"name":72,"class":73},"Holycross Cancer Center Kielce","UNKNOWN",{"name":75,"class":6},"Medical University of Lublin",{"name":77,"class":6},"Hospital del Mar",{"name":79,"class":6},"Hospital Vall d'Hebron",{"name":81,"class":6},"Royal Cornwall Hospitals Trust",{"name":83,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"name":85,"class":6},"The Netherlands Cancer Institute",{"name":87,"class":6},"Canisius-Wilhelmina Hospital",{"name":89,"class":6},"Catharina Ziekenhuis Eindhoven",{"name":91,"class":6},"Erasmus Medical Center",{"name":93,"class":6},"Leiden University Medical Center","100333482","promote-study-prediction-of-response-of-hormonal-treatment-in-advanced-and-recurrent-endometrial-cancer-100333482",false,"NCT03621904","PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer","PROMOTE","Inclusion Criteria:\n\n* Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer\n* All histologic types of endometrial carcinoma\n* Planned treatment with any type of hormonal therapy\n* Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy.\n\nExclusion Criteria:\n\n* Adjuvant hormonal therapy started following complete resection of endometrial carcinoma\n* Synchronous use of hormonal therapy for other indications\n* Endometrial sarcoma or endometrial stroma cell sarcoma","FEMALE","18 Years","110 Years",{"count":105,"type":106},150,"ESTIMATED","2 Years","OBSERVATIONAL","The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy",[111,112,113],"Endometrial Cancer Stage III","Endometrial Cancer Stage IV","Endometrial Cancer Recurrent",[115,116,117,118],"Hormonal therapy","Endocrine therapy","Translational research","Tumor factors","2023-01-17",{"date":121,"type":122},"2023-01-18","ACTUAL",{"date":124,"type":122},"2022-10-15",{"date":126,"type":106},"2027-09-01",{"name":5,"class":6},1]